Focused on discovering and developing small‑molecule therapies for metabolic and cardiovascular diseases, the company operates as a clinical‑stage biopharmaceutical developer with a pipeline built from its proprietary gene‑science research platform. Its lead programs include sotagliflozin, studied f...
1 member of Congress has disclosed 1 trade in Lexicon Pharmaceuticals Inc. (LXRX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-08-29 | Rohit Khanna | buy | $1K – $15K |